m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation (Q51122670)

30 March 2018

title

m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation (English)

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

20 May 2024

author name string

W. K. Goodman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

C. J. McDougle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

L. H. Price

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

L. C. Barr

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

O. F. Hills

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

J. F. Caplik

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

D. S. Charney

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

G. R. Heninger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

20 May 2024

language of work or name

English

0 references

publication date

1 August 1995

1 reference

30 March 2018

full work available at URL

https://doi.org/10.1016/0006-3223(94)00235-u

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7578657

https://api.elsevier.com/content/article/PII:000632239400235U?httpAccept=text/xml

20 May 2024

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

https://api.elsevier.com/content/article/PII:000632239400235U?httpAccept=text/plain

20 May 2024

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

20 May 2024

published in

Biological Psychiatry

1 reference

30 March 2018

volume

38

1 reference

30 March 2018

issue

3

1 reference

30 March 2018

page(s)

138-149

1 reference

30 March 2018

Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats

20 May 2024

3

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies

20 May 2024

4

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

(—)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone

20 May 2024

5

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects

20 May 2024

6

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptors

20 May 2024

7

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats

20 May 2024

8

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

20 May 2024

9

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

The Yale-Brown Obsessive Compulsive Scale. II. Validity

20 May 2024

10

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Development of a Rating Scale for Primary Depressive Illness

20 May 2024

14

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder

20 May 2024

16

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonergic Function in Obsessive-Compulsive Disorder

20 May 2024

17

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

The MCPP challenge test in schizophrenia: hormonal and behavioral responses

20 May 2024

18

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects

20 May 2024

19

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

m-Chlorophenylpiperazine as a probe of serotonin function

20 May 2024

20

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects

20 May 2024

21

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia

20 May 2024

23

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers

20 May 2024

24

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonin-releasing effects of substituted piperazines in vitro

20 May 2024

25

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder

20 May 2024

26

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.

20 May 2024

27

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects

20 May 2024

29

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls

20 May 2024

31

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment

20 May 2024

32

1 reference

https://api.crossref.org/works/10.1016/0006-3223(94)00235-U

20 May 2024

Identifiers

1 reference

30 March 2018

1 reference

30 March 2018